Related Experiment Video
Updated: Sep 29, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
Anusha Chegu1, Sandeep Surendra Panikar2, Patricia M R Pereira2
1Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, United States of America; Department of Biology, Washington University School of Medicine, St. Louis, MO 63130-4899, United States of America.
Abstract:
Targeted tumor therapies of receptor tyrosine kinases (RTK) do not work for every patient with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation mechanisms, and other aspects of disease biology. Over the last years, the combination of non-invasive positron emission tomography (PET) with non-pharmacological doses of an RTK-specific antibody has shown the ability to study cancer biology in real-time and in the whole body of living subjects at the early stages of the disease and in response to therapies. Many RTK-specific antibody-PET imaging conjugates exist in the clinics and show potential for earlier diagnosis and accurate management of oncology patients. Herein, our review concisely focuses on clinical and preclinical data of RTK-targeted PET imaging to detect two significant biological mechanisms of tumor resistance - RTK heterogeneity and RTK co-activation. This mini-review provides an overview of RTK-targeted PET imaging studies of the last 4 years and gives collective information on how it may assist prognostic information and image disease recurrence.
Insights
Receptor tyrosine kinase (RTK)-targeted therapies are limited by tumor resistance. RTK-targeted PET imaging offers real-time, whole-body insights into RTK heterogeneity and co-activation, aiding cancer management and recurrence detection.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Targeted therapies for receptor tyrosine kinases (RTKs) show variable efficacy due to tumor heterogeneity and co-activation.
- Non-invasive positron emission tomography (PET) combined with RTK-specific antibodies allows real-time, in-vivo study of cancer biology.
- RTK-targeted antibody-PET imaging conjugates are emerging tools for oncology patient management.
Purpose of the Study:
- To review clinical and preclinical data on RTK-targeted PET imaging.
- To focus on detecting RTK heterogeneity and co-activation as mechanisms of tumor resistance.
- To provide an overview of recent RTK-targeted PET imaging studies.
Main Methods:
- Review of clinical and preclinical studies published within the last 4 years.
- Focus on studies utilizing RTK-specific antibody-PET imaging conjugates.
- Analysis of data related to RTK heterogeneity and co-activation in tumors.
Main Results:
- RTK-targeted PET imaging can visualize RTK heterogeneity and co-activation in real-time.
- This imaging modality shows potential for early cancer diagnosis and treatment response assessment.
- Studies demonstrate the utility of RTK-targeted PET in understanding tumor resistance mechanisms.
Conclusions:
- RTK-targeted PET imaging is a valuable tool for assessing tumor resistance mechanisms like RTK heterogeneity and co-activation.
- This technique aids in prognostic information and imaging disease recurrence.
- RTK-targeted antibody-PET conjugates hold significant promise for personalized oncology.
More Related Videos
Related Concept Videos
Receptor Tyrosine Kinases
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

